Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Scripps Research Scientists Observe Human Neurodegenerative Disorder In Fruit Flies
A team of scientists from The Scripps Research Institute, Katholeike Universiteit Leuven, and the University of Antwerp, Belgium, among other institutions, has created a genetically modified fruit fly that mimics key features of Charcot-Marie-Tooth disease, a common neurodegenerative disorder that strikes about one out of every 2,500 people in the United States.
generic viagra online
HIV Testing Can Save Thousands Of Lives, CDC Official Says
"Although HIV/AIDS continues to pose a serious threat to the nation"s health, HIV testing is a powerful weapon against the disease," Kevin Fenton, director of CDC"s National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, writes in a CNN.com opinion piece. Fenton writes that every 9 1/2 minutes someone in the U.S. becomes infected with HIV. "That"s 56,000 people every year," Fenton writes, adding, "But there"s something we can all do to help protect ourselves and our partners from this disease - get tested for HIV." He continues, "By increasing the number of people who know their HIV status, we can decrease the number of new HIV infections, and help save thousands of lives" (Fenton, CNN.com, 6/26).
News of the day
AOSSM Presents Prestigious Research Awards
In order to recognize and encourage cutting-edge research in key areas of orthopaedic sports medicine, the American Orthopaedic Society for Sports Medicine (AOSSM) will present eight research awards and two grants during its Annual Meeting, July 9-12th in Keystone, Colorado. As a leader in orthopaedic sports medicine, AOSSM annually provides more than $150,000 to research initiatives and projects around the country. Highlights of this year"s award recipients include:
Sexual Health

UCB Launches Vimpat In The US For Add-On Treatment Of Epilepsy In Adults

is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Vimpat® solution for infusion is an alternative for patients when oral administration is temporarily not feasible. Contraindications: Hypersensitivity to the active substance or to peanuts or soya or to any of the excipients; known second- or third-degree atrioventricular (AV) block. Special warnings and precautions for use: Treatment with lacosamide has been associated with dizziness which could increase the occurrence of accidental injury or falls. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicine. Prolongations in PR interval with lacosamide have been observed in clinical studies. Lacosamide should be used with caution in patients with known conduction problems or severe cardiac disease such as a history of myocardial infarction or heart failure. Caution should especially be exerted when treating elderly patients as they may be at an increased risk of cardiac disorders or when lacosamide is used in combination with products known to be associated with PR prolongation. Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents. Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge. Undesirable effects: The most common adverse reactions (>10%) are dizziness, headache, diplopia, and nausea. Other common adverse reactions (1初%) are depression, balance disorder, coordination abnormal, memory impairment, cognitive disorder, somnolence, tremor, nystagmus, vision blurred, vertigo, vomiting, constipation, flatulence, pruritus, gait disturbance, asthenia, fatigue, fall, and skin laceration. Refer to the European Summary of Product Characteristics for full prescribing information. http://www.emea.europa.eu/humandocs/PDFs/EPAR/vimpat/H-863-PI-en.pdf (Accessed 02.03.09) Andrea Levin Cooney Waters Group, Inc.

Pages: 1 [2] 


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

Copyright 2009